Shutdown of immunological priming and presentation after in vivo administration of adenovirus

Gene Therapy ◽  
2011 ◽  
Vol 19 (11) ◽  
pp. 1095-1100 ◽  
Author(s):  
R M Sutherland ◽  
S L Londrigan ◽  
J L Brady ◽  
H Azher ◽  
E M Carrington ◽  
...  
1983 ◽  
Vol 50 (03) ◽  
pp. 652-655 ◽  
Author(s):  
F Bauer ◽  
P Schulz ◽  
G Reber ◽  
C A Bouvier

SummaryThree mucopolysaccharides (MPS) used in the treatment of degenerative joint disease were compared to heparin to establish their relative potencies on 3 coagulation tests, the aPTT, the antifactor X a activity and the dilute thrombin time. One of the compounds, Arteparon®, was one fourth as potent as heparin on the aPTT, but had little or no influence on the 2 other tests. Further in vitro studies suggested that Arteparon® acted at a higher level than factor Xa generation in the intrinsic amplification system and that its effect was independent of antithrombin III. In vivo administration of Arteparon® confirmed its anticoagulant properties, which raises the question of the clinical use of this MPS.


Cells ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 132
Author(s):  
Johanna Simon ◽  
Gabor Kuhn ◽  
Michael Fichter ◽  
Stephan Gehring ◽  
Katharina Landfester ◽  
...  

Understanding the behavior of nanoparticles upon contact with a physiological environment is of urgent need in order to improve their properties for a successful therapeutic application. Most commonly, the interaction of nanoparticles with plasma proteins are studied under in vitro conditions. However, this has been shown to not reflect the complex situation after in vivo administration. Therefore, here we focused on the investigation of magnetic nanoparticles with blood proteins under in vivo conditions. Importantly, we observed a radically different proteome in vivo in comparison to the in vitro situation underlining the significance of in vivo protein corona studies. Next to this, we found that the in vivo corona profile does not significantly change over time. To mimic the in vivo situation, we established an approach, which we termed “ex vivo” as it uses whole blood freshly prepared from an animal. Overall, we present a comprehensive analysis focusing on the interaction between nanoparticles and blood proteins under in vivo conditions and how to mimic this situation with our ex vivo approach. This knowledge is needed to characterize the true biological identity of nanoparticles.


1993 ◽  
Vol 149 (1) ◽  
pp. 39-49 ◽  
Author(s):  
Jolanta E. Kunicka ◽  
Mary Anne Talle ◽  
Georgetta H. Denhardt ◽  
Martha Brown ◽  
Laura A. Prince ◽  
...  

Heart Rhythm ◽  
2013 ◽  
Vol 10 (11) ◽  
pp. 1743
Author(s):  
S. de Jong ◽  
L. van Middendorp ◽  
R.H.A. Hermans ◽  
J.M.T. de Bakker ◽  
M.F.A. Bierhuizen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document